Enlivex Therapeutics Ltd. financial data

Symbol
ENLV on Nasdaq
Industry
Pharmaceutical Preparations
Location
37 Dereh Menachem Begin St., 15 Th Floor, Tel Aviv, Israel
State of incorporation
Israel
Fiscal year end
December 31
Former names
Bioblast Pharma Ltd. (to 3/18/2019), BIO BLAST PHARMA LTD. (to 9/12/2016)
Latest financial report
6-K - Q2 2024 - Aug 30, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.6M shares +0.96%
Common Stock, Shares, Outstanding 20.9M shares +12.3%
Common Stock, Value, Issued 2.39M USD +11.7%
Weighted Average Number of Shares Outstanding, Basic 19.5M shares +5.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2M USD -60.3%
General and Administrative Expense 987K USD -38.8%
Costs and Expenses 1M USD
Operating Income (Loss) -2.99M USD +55.1%
Net Income (Loss) Attributable to Parent -3.1M USD +54.4%
Earnings Per Share, Basic -0.16 USD/shares +56.8%
Earnings Per Share, Diluted -0.16 USD/shares +56.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.75M USD +8.36%
Marketable Securities, Current 228K USD
Other Assets, Current 6.59M USD
Assets, Current 28.6M USD -7.2%
Property, Plant and Equipment, Net 1.16M USD -87.9%
Operating Lease, Right-of-Use Asset 870K USD -81.6%
Other Assets, Noncurrent 1.28M USD
Assets 31.9M USD -39.8%
Accounts Payable, Current 303K USD
Employee-related Liabilities, Current 314K USD -48.7%
Accrued Liabilities, Current 4M USD -14.1%
Liabilities, Current 2.84M USD -43.1%
Operating Lease, Liability, Noncurrent 499K USD -86.5%
Other Liabilities, Noncurrent 499K USD
Liabilities 3.34M USD -61.6%
Retained Earnings (Accumulated Deficit) -119M USD -23%
Stockholders' Equity Attributable to Parent 28.6M USD -35.6%
Liabilities and Equity 31.9M USD -39.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 45M shares 0%
Common Stock, Shares, Issued 20.9M shares +12.3%
Common Stock, Par or Stated Value Per Share 0.4 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.17M USD +7.87%
Deferred Tax Assets, Valuation Allowance 22.3M USD -23.1%
Deferred Tax Assets, Gross 22.3M USD -23.1%
Operating Lease, Liability 835K USD -80.9%
Depreciation 176K USD +44.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.91M USD -841%
Lessee, Operating Lease, Liability, to be Paid 945K USD
Property, Plant and Equipment, Gross 4.18M USD -56.4%
Operating Lease, Liability, Current 336K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 193K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 355K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +88.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 117K USD
Deferred Tax Assets, Operating Loss Carryforwards 15.4M USD -35.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 89K USD
Additional Paid in Capital 139M USD +1.68%
Share-based Payment Arrangement, Expense 388K USD -24.1%